Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03GCJ
|
|||
| Former ID |
DAP000065
|
|||
| Drug Name |
Carteolol
|
|||
| Synonyms |
Carteololum; Carteolol HCl; Carteolol Monohydrochloride; Arteolol (TN); Arteoptic (TN); Calte (TN); Carteol (TN); Carteolol (INN); Carteolol [INN:BAN]; Carteololum [INN-Latin]; Cartrol (TN); Elebloc (TN); Endak (TN); Glauteolol (TN); Mikelan (TN); Ocupress (TN); Poenglaucol (TN); Singlauc (TN); Teoptic (TN); 5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-3,4-dihydroquinolin-2(1H)-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Glaucoma/ocular hypertension [ICD-11: 9C61; ICD-9: 365] | Approved | [1] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Company |
CIBA Vision Sterile Mfg
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H24N2O3
|
|||
| Canonical SMILES |
CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O
|
|||
| InChI |
1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)
|
|||
| InChIKey |
LWAFSWPYPHEXKX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 51781-06-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9091, 7387302, 7978865, 8151708, 11466474, 11467594, 11486167, 14849226, 29221743, 46507513, 47676636, 47750978, 48049811, 48199247, 48273825, 48415706, 49699359, 50043719, 50124258, 51091932, 56464106, 57321385, 74586165, 85209493, 85788887, 99246440, 103220917, 103972128, 104301010, 125351949, 126686934, 128549615, 134223610, 134337393, 135001302, 137248593, 142047552, 152057655, 160963866, 163164682, 163419007, 164829321, 172892987, 178103718, 179150538, 184536606, 198992672, 223672177, 226413058, 241091236
|
|||
| ChEBI ID |
CHEBI:3437
|
|||
| ADReCS Drug ID | BADD_D00372 ; BADD_D00373 | |||
| SuperDrug ATC ID |
C07AA15; S01ED05
|
|||
| SuperDrug CAS ID |
cas=051781067
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-1 (ADRB1) | Target Info | Agonist | [2], [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Gap junction | ||||
| Salivary secretion | ||||
| Dilated cardiomyopathy | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta1 adrenergic receptor signaling pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Partial agonistic effects of carteolol on atypical beta-adrenoceptors in the guinea pig gastric fundus. Jpn J Pharmacol. 2000 Nov;84(3):287-92. | |||
| REF 3 | Effects of prolonged treatment with beta-adrenoceptor antagonist, carteolol on systemic and regional hemodynamics in stroke-prone spontaneously hypertensive rats. J Pharmacobiodyn. 1991 Feb;14(2):94-100. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.